Skip to main content
. 2022 Mar 9;113(5):1808–1820. doi: 10.1111/cas.15304

FIGURE 1.

FIGURE 1

Sampling intervals for targeted next generation sequencing (NGS) circulating tumor DNA analysis in patients with metastatic breast cancer. Patients were followed until progressive disease, 24 months, or the cut‐off date (September 30, 2020), whichever comes first. Radiology assessment and tumor markers carcinoembryonic antigen (CEA), cancer antigen (CA) 15‐3 timeline might differ as decided by clinicians. Some figures in Figure 1 were adapted from Servier Medical Art (https://smart.servier.com)